Plus, news about the Novo Nordisk Foundation, Assembly Biosciences, Cidara Therapeutics, Minovia and Celyad Oncology:
Arbutus reacquires China rights to hepatitis B candidate: The company licensed the rights to imdusiran in ...
↧